Singapore, Sept. 24 -- Mayo Clinic Laboratories and Pathology Asia Holdings have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.

Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together Mayo's global clinical and diagnostic expertise with the regional healthcare network, capabilities and market knowledge of PAH and its genomics subsidiary, LifeStrands Genomics.

William Morice II, M.D., Ph.D., President and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH.

Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics.

May...